Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
about
KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancerSoy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future PerspectivesNuclear PI3K signaling in cell growth and tumorigenesisFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?XB130-A Novel Adaptor Protein: Gene, Function, and Roles in TumorigenesisSrc Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun PathwayRelationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesCurcumin Suppresses Proliferation and Migration of MDA-MB-231 Breast Cancer Cells through Autophagy-Dependent Akt DegradationPreclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancerActivity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypesStachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of Akt and ERK pathwaysZeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.Estradiol Suppresses TLR4-triggered Apoptosis of Decidual Stromal Cells and Drives an Anti-inflammatory TH2 Shift by Activating SGK1.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysUnique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsGemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways.hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.Smarter drugs emerging in pancreatic cancer therapy.The AURORA initiative for metastatic breast cancer.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.Unique molecular landscapes in cancer: implications for individualized, curated drug combinations.Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerP-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.p70 S6-kinase mediates the cooperation between Akt1 and Mek1 pathways in fibroblast-mediated extracellular matrix remodelingStimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.Multiple gene aberrations and breast cancer: lessons from super-responders.Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.Advances in small-molecule drug discovery for triple-negative breast cancer.An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead DiscoveryThe impact of polyphenols on chondrocyte growth and survival: a preliminary reportA MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells.How interacting pathways are regulated by miRNAs in breast cancer subtypes.Berberine displays antitumor activity in esophageal cancer cells in vitro.Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.EIF2S3Y suppresses the pluripotency state and promotes the proliferation of mouse embryonic stem cells
P2860
Q24296484-DD62E180-EA82-4082-AE56-1D1DE0A2B76EQ26772042-ECBF06DF-0CE1-4955-87A9-53457243814DQ26859127-75746F57-08CC-48A7-A599-BB17926191E1Q28084982-FDE14284-F25F-4078-9708-D445BA6914D4Q28388570-973F7731-D5A5-4DD8-9BF5-07D5E74E3AB7Q28468471-4E32ECCE-DCD5-4892-A68F-3CB91F7DF2DCQ28542662-24614527-FDF9-4A1C-B950-59B5B631CE12Q28552250-13CEAFA6-0683-437E-A16D-1CF3592DCF66Q31140123-8159AE17-3DD4-4A44-A5D0-8858E4613F33Q33591690-35C83BA0-DAA2-4AE8-9E73-71C1A6D290A2Q33608593-E31053F0-6D64-423D-A256-76DBA9D6B279Q33623156-2B94EB8D-6B7A-42AE-BB8F-2B0527779720Q33687272-3351B98D-C568-43E7-B5DB-81D3AABB9F91Q33703276-410258D7-2D71-4CA1-A8D4-29E14A0483DEQ33737298-9C07532C-4F5B-44EA-8EB1-55C4CDABE7EFQ33756991-605766A4-E71A-4501-AFF8-F67512E40333Q33779061-7A950544-BC24-42F3-8812-F05F76A13306Q33913833-F4C9B8B7-C56C-4545-90DE-E714698990F4Q34410212-302299A9-125A-4ED6-A1B3-D7C442039F69Q34499602-C2508CF9-1ACD-49B7-BE6A-6BE5DE8E976BQ34654793-314BAC6F-F667-4605-A085-DC728365C438Q34914935-E3CF00F3-81DC-479B-851B-8ACED4E903DFQ34938532-F1CA568B-1CC1-4D45-9D21-3861D74DA6CDQ35072441-29F77248-E21F-4C6E-B2FF-35ABDF0F9DB2Q35288044-7651310D-3216-4A9D-96C9-8A7BB7980262Q35583904-9961600C-FFA8-48F6-A8BC-1FABC92B18E7Q35598268-C057BA89-CAF3-4CEB-9FAA-5F4F7ABA4610Q35610049-4B0E1514-DF36-4BF8-B0A9-9F66C036ECB7Q35645466-BFD31B5B-BAB4-4B06-9D63-F069B471418FQ35675442-F2AC5361-AD7E-41E3-894C-D30B45E6DF8AQ35818491-3A665CCA-BF5C-49E1-AA5F-A8B1F5850358Q35861440-43949159-C7ED-4761-AC48-F1B85DC3EB68Q36127934-4C4DFF09-1254-4295-B6A6-65962FA9D7B5Q36140634-8EA2D75D-49D3-4ED9-9D36-76BA0683237AQ36265801-D6AED0AE-E90A-4117-8A59-5A3EE5F5B160Q36276533-339F257A-AED8-458C-A60D-4EA11BFAC79DQ36361429-84869773-98B3-4CD8-8928-2557532C9999Q36413242-B67B81B6-DD1D-4C9F-AA0F-140461B33FCEQ36546319-796EB045-0067-4212-B9B1-34F0E8A91206Q36998244-D1D11114-AC00-4003-ACBF-9E0C2AD7DFD7
P2860
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@ast
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@en
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@nl
type
label
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@ast
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@en
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@nl
prefLabel
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@ast
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@en
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@nl
P2093
P50
P1476
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
@en
P2093
Janet E Dancey
Kamal S Saini
Michail Ignatiadis
Otto Metzger-Filho
P304
P356
10.1016/J.CTRV.2013.03.009
P577
2013-05-03T00:00:00Z